Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Accelerate Diagnostics reports Q1 losses but shows growth potential

Accelerate Diagnostics showcased growth potential with customer acquisitions, Wave program progress, and strategic partnerships, despite facing cost management challenges.
The company's focus on innovation, customer engagement, and operational efficiency positions it for market expansion and technology advancement in the diagnostics sector.
Addressing expense control, successful commercialization of new programs, and sustaining growth momentum are key focus areas for Accelerate Diagnostics to drive profitability.

Accelerate Diagnostics reports Q3 milestones amidst financial challenges

Accelerate Diagnostics demonstrated financial performance with notable milestones achieved in Q3 2024.
While facing challenges in managing cash burn and addressing analyst inquiries, the company showcased strengths in commercial progress and innovation.
Opportunities for growth and market leadership exist through leveraging recent FDA clearances and expanding into new markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade

Cardlytics

G-III Apparel Group

Ngm Biopharmaceuticals Inc

OPKO Health

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Corporate Insiders Pull the Trigger on These 5 Stocks

Clearway Energy

Five Point Holdings

International Flavors & Fragrances

MGM Resorts

Myovant Sciences

National CineMedia

XPO Logistics

Daily Insider Ratings Round Up 4/1/20

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2019 Results - Earnings Call Transcript

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline

Simulations Plus

Two of the sector's biggest winners of the past 10 years are still flying under the radar. Which looks like the better buy today?

2 Growing Healthcare Stocks You Should Know

ABIOMED

ACADIA Pharma

DexCom

Exact Sciences

Jazz Pharmaceuticals

Neurocrine Biosciences

NeoGenomics

Repligen

The 10 Best Healthcare Stocks of the Decade

Accelerate Diagnostics, Inc. (AXDX) CEO Larry Mehren on Q3 2019 Results - Earnings Call Transcript

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%

Finally, reaching a positive inflection point for devices under contract.

Accelerate Diagnostics, Inc.: The Snowball Effect Is Just Beginning

Accelerate Diagnostics' (AXDX) CEO Larry Mehren on Q2 2019 Results - Earnings Call Transcript

Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q1 2019 Results - Earnings Call Transcript

Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for

News for Accelerate Diagnostics Stock (AXDX)